Published on: March 26, 2014
by Business Standard:
Scientists have developed a test that could predict the risk of developing Alzheimer’s disease by detecting abnormalities in spinal fluid.
The test detects tiny, misfolded protein fragments called beta amyloid oligomers in cerebrospinal fluid taken from patients. Scientists used to think amyloid plaques were the problem in Alzheimer’s disease.
“Now it seems clear that the aggregates are not the main culprits, it’s their precursors, so-called beta amyloid oligomers,” said Claudio Soto of the University of Texas Medical School at Houston.
“This is the key molecule and could be the best, most reliable way to make an early diagnosis,” Soto said. “Those beta amyloid oligomers may be circulating in the body for years if not decades before cognitive symptoms arise,” Soto added.
In the new study, Soto and his colleagues applied a technology they developed earlier for detection of the misfolded proteins responsible for prion diseases including mad cow disease.
Their protein misfolding cyclic amplification (PMCA) technology works by amplifying existing misfolded proteins and then breaking them up into smaller pieces.
When mixed with the equivalent, normal protein, the misfolded fragments act as seeds for the formation, in the case of beta amyloid, of amyloid clumps like those found in the Alzheimer’s brain.
The researchers showed that their PMCA technology can detect beta amyloid oligomers at incredibly low concentrations.
In principle, their earlier prion work suggests it might be possible to detect even a single particle of misfolded beta amyloid.
Most importantly, Soto and his colleagues were able to distinguish between patients with Alzheimer’s disease and those with other neurodegenerative or neurological disorders with 90 per cent sensitivity and 92 per cent specificity by applying their test to cerebrospinal fluid samples.
The next step, Soto said, is to adapt the technology for use with blood or urine samples, which would be much easier to obtain for screening perfectly healthy people for biochemical signs of Alzheimer’s disease.
If additional research can confirm the utility of the test in Alzheimer’s and perhaps other conditions (eg Parkinson’s disease), Soto said a US Food and Drug Administration-approved test could be on the market in as little as three years.
The findings were reported in the Cell Press journal Cell Reports.
Older people who report greater levels of social engagement have more robust gray matter in regions of the brain relevant in dementia, according to new research led by scientists at the University of Pittsburgh Graduate School of...
In a new study, University of Nebraska–Lincoln sociologist Marc A. Garcia explored how educational attainment can benefit cognitive health in later life, and whether there are differences in its benefits among minorities. Garcia and his co-authors...
A genetic variation in some people may be associated with cognitive decline that can’t be explained by deposits of two key proteins associated with Alzheimer’s disease, amyloid β and tau, according to a study...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.